601
mAbexperimental
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Nov 12, 2018 (NCT04468997)
Timeline
Indications
Mechanism of action
- Vascular endothelial growth factor AINHIBITOR
VEGFA inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05520177 | Phase 3 | Sep 30, 2022 | Sunshine Lake Pharma Co., Ltd., Tianjin Medical University |
| NCT04922151 | Phase 2 | Jun 4, 2021 | Chinese Academy of Medical Sciences, Sunshine Lake Pharma Co., Ltd. |
| NCT04667897 | Phase 2 | Dec 31, 2020 | Peking University, Sunshine Lake Pharma Co., Ltd. |
| NCT04667910 | Phase 2 | Dec 31, 2020 | Sunshine Lake Pharma Co., Ltd., Tianjin Medical University |
| NCT04151407 | Phase 1 | Mar 8, 2019 | Sunshine Lake Pharma Co., Ltd. |
| NCT04468997 | Phase 1 | Nov 12, 2018 | Sunshine Lake Pharma Co., Ltd. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sunshine Lake Pharma Co., Ltd. | For profit | 6 | 6 | 3 | 2018 |
| Tianjin Medical University | Academic/Hospital | 2 | 0 | 2 | 2020 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1